AB SCIENCE
Discipline serving the patients

PRESS RELEASE

AB SCIENCE ANNOUNCES THE SUCCESSFUL SETTLEMENT AND DELIVERY OF SECURITIES ISSUED AS PART OF ITS €14.2 MILLION PRIVATE PLACEMENT ANNOUNCED ON AUGUST 10, 2026

Paris, August 17, 2026, 7.30am CET

AB Science S.A. (the "Company" or **"AB Science**," Euronext – FR0010557264 – AB) today announces the successful settlement and delivery of the securities issued as part of its capital increases subscribed to by a limited number of investors and announced on August 10, 2026 (**the "Private** Placement").

As announced on August 10, 2026, the Private Placement, totaling EUR 14.2 million (including the issuance premium and excluding the potential exercise of BSA-1 and BSA-2 warrants), was carried out through the issuance, without preemptive subscription rights and without a priority period, of:

(i) 3,606,560 new common shares of the Company (**the "New** Shares") issued at a price of EUR 0.61 per share, each accompanied by a stock subscription warrant (a "BSA-1") – five BSA-1s entitle their holder to subscribe for three new common shares of the Company at a price of EUR 1.00 per common share; and

(ii) 19,672,132 New Shares issued at a price of EUR 0.61 per share, each accompanied by a stock subscription warrant (a "BSA-2") – four BSA-2s entitle their holder to subscribe for seven new common shares of the Company at a price of EUR 1.00 per common share.

If all BSA-1s and BSA-2s are exercised, a total of 36,590,166 additional common shares of the Company will be issued, representing total additional proceeds of approximately EUR 36.6 million. Thus, taking into account the issuance of the New Shares and the potential future exercise of the BSA-1 and BSA-2 warrants, the total amount of the Private Placement will amount, if applicable, to approximately EUR 50.8 million.

On this basis, the ownership interest of a shareholder holding 1.00% of the Company's share capital prior to the completion of the Private Placement and who did not subscribe to it is now 0.7747% on an undiluted basis and 0.6072% on a diluted basis prior to the exercise of the BSA-1 and BSA-2 warrants, and 0.5721% on a non-diluted basis and 0.5332% on a diluted basis after the exercise of BSA-1 and BSA-2 warrants.

Finally, it is confirmed that Stéphane Ledermann, the Company's Chairman and Chief Executive Officer, participated in the Private Placement in the amount of EUR 150,000.

About masitinib

Masitinib is a novel oral tyrosine kinase inhibitor that is being developed to target mast cells and macrophages, key immune cells, through inhibition of a limited number of kinases. Through its activity on mast cells and microglial cells and therefore its inhibitory effect on the activation of the inflammatory process, masitinib may have an effect on the course of central nervous system diseases.

About AB8939

AB8939 is a new synthetic microtubule-destabilizing drug candidate. Preclinical data suggests that AB8939 has broad anticancer activity, with a notable advantage over standard chemotherapies that target microtubules of being able to overcome P-glycoprotein (Pgp) and myeloperoxidase (MPO) mediated drug resistance. Development of drug resistance often restricts the clinical efficacy of microtubule-targeting chemotherapy drugs (for example, taxanes and vinca alkaloids); thus, AB8939 has the potential to be developed in numerous oncology indications.

About AB Science

Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment. AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine and is being developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB). Further information is available on AB Science's website: www.ab-science.com.

Disclaimer

This press release and the information contained herein do not constitute an offer to subscribe or purchase, or the solicitation of an order to purchase or subscribe, for the New Shares in the United States of America or in any other jurisdiction. Securities may not be offered or sold in the United States of America absent registration under the U.S. Securities Act or an exemption from registration under the U.S. Securities Act. AB Science does not intend to make a public offering of the New Shares in the United States of America or in any other jurisdiction. The distribution of this press release may be subject to legal or regulatory restrictions in certain countries. Persons in possession of this press release should inform themselves of and observe any local restrictions.

The information contained herein is subject to change without notice. This information contains forward-looking statements, which are not guarantees of future performance. These statements are based on the current expectations and beliefs of AB Science's management and are subject to several factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. AB Science and its affiliates, directors, officers, employees, consultants or agents do not undertake, and are not under any obligation, to release any updates to any forward-looking statement or to revise any forward-looking statement.

For additional information, please contact:
AB Science Financial communication and public relations
investors@ab-science.com